Vanda Pharmaceuticals Inc. Common Stock VNDA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-08T09:15:14.724Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T23:54:46.992168405Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-08T09:15:14.340480+00:00
Vanda Pharmaceuticals Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.25 | 90.7% | 18.2% | |||
| 25Δ | 3.34 | 86.4% | 16.3% | |||
| 30Δ | 3.44 | 82.0% | 14.3% | |||
| 35Δ | 4.49 | 121.2% | 20.0% | 3.53 | 77.7% | 12.3% |
| 40Δ | 4.24 | 100.4% | 13.7% | 3.63 | 73.3% | 10.3% |
| 45Δ | 4.00 | 80.4% | 7.6% | 3.73 | 69.0% | 8.3% |
| 50Δ | 3.86 | 95.8% | 7.2% | 3.82 | 64.6% | 6.4% |
| 55Δ | 3.73 | 111.2% | 6.7% | |||
| 60Δ | 3.59 | 126.5% | 6.3% | |||
| 65Δ | 3.45 | 141.9% | 5.8% | |||
| 70Δ | 3.32 | 157.3% | 5.4% | |||
| 75Δ | 3.18 | 172.6% | 5.0% | 7.45 | 350.0% | 6.9% |
| 80Δ | 3.05 | 188.0% | 4.5% | 8.28 | 348.8% | 5.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.25
- IV
- 90.7%
- B/E move
- 18.2%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.34
- IV
- 86.4%
- B/E move
- 16.3%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.44
- IV
- 82.0%
- B/E move
- 14.3%
35Δ
- Pseudo strike
- 4.49
- IV
- 121.2%
- B/E move
- 20.0%
- Pseudo strike
- 3.53
- IV
- 77.7%
- B/E move
- 12.3%
40Δ
- Pseudo strike
- 4.24
- IV
- 100.4%
- B/E move
- 13.7%
- Pseudo strike
- 3.63
- IV
- 73.3%
- B/E move
- 10.3%
45Δ
- Pseudo strike
- 4.00
- IV
- 80.4%
- B/E move
- 7.6%
- Pseudo strike
- 3.73
- IV
- 69.0%
- B/E move
- 8.3%
50Δ
- Pseudo strike
- 3.86
- IV
- 95.8%
- B/E move
- 7.2%
- Pseudo strike
- 3.82
- IV
- 64.6%
- B/E move
- 6.4%
55Δ
- Pseudo strike
- 3.73
- IV
- 111.2%
- B/E move
- 6.7%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 3.59
- IV
- 126.5%
- B/E move
- 6.3%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 3.45
- IV
- 141.9%
- B/E move
- 5.8%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 3.32
- IV
- 157.3%
- B/E move
- 5.4%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 3.18
- IV
- 172.6%
- B/E move
- 5.0%
- Pseudo strike
- 7.45
- IV
- 350.0%
- B/E move
- 6.9%
80Δ
- Pseudo strike
- 3.05
- IV
- 188.0%
- B/E move
- 4.5%
- Pseudo strike
- 8.28
- IV
- 348.8%
- B/E move
- 5.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 157.95% | |
| 101.97% | |
| 109.09% | |
| 124.25% | |
| 108.73% | |
| 105.84% | |
| 106.37% | |
| 159.66% | |
| 115.13% |
Biotechnology
VOR
Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in…
More →VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
More →VRTX
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
More →VSTM
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in…
More →VYGR
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. The company is headquartered…
More →WHWK
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. The company is headquartered in…
More →